Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic...
Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today...
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing...
AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics. SANTA CLARA, Calif., May 30,...
PEARLAND, Texas, May 30, 2025 /PRNewswire/ -- Cornerstone Specialty Network ("Cornerstone"), a leading provider of innovative solutions for specialty providers...
NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater...
Lumea and AIxMed team up to bring AI driven urine cytology to Lumea's platform, targeting improved bladder cancer diagnostics. SANTA...
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 30, 2025 /PRNewswire/ -- The concept...
BOSTON, May 30, 2025 /PRNewswire/ -- Velsera announces that its clinical Knowledgebase is powering the interpretation framework behind Illumina's TruSight™ Oncology...
Findings show Black and Hispanic Patients Have 30% Higher Risk of Advanced-Stage DiagnosisBOSTON--(BUSINESS WIRE)--Ontada®, a leader in real-world oncology data...
Findings show Black and Hispanic Patients Have 30% Higher Risk of Advanced-Stage DiagnosisBOSTON--(BUSINESS WIRE)--Ontada®, a leader in real-world oncology data...
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain...
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain...
David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1,...
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing...
May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage...
SYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for...
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq:...
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence...
REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology...